Who are Oral Capsule Mexiletine (IR)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): IV lignocaine bolus and infusion.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oral-capsule-mexiletine-ir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Oral Capsule Mexiletine (IR) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oral Capsule Mexiletine (IR) (Oral Capsule Mexiletine (IR)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Class IB antiarrhythmic agent. Area: Cardiovascular.

phase 3 Class IB antiarrhythmic agent Cardiac voltage-gated sodium channel (Nav1.5) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Oral Capsule Mexiletine (IR) (Oral Capsule Mexiletine (IR)) — Lupin Ltd.. Mexiletine is a class IB antiarrhythmic agent that blocks cardiac sodium channels to suppress abnormal electrical activity and restore normal heart rhythm.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oral Capsule Mexiletine (IR) TARGET	Oral Capsule Mexiletine (IR)	Lupin Ltd.	phase 3	Class IB antiarrhythmic agent	Cardiac voltage-gated sodium channel (Nav1.5)
IV lignocaine bolus and infusion	IV lignocaine bolus and infusion	University of Auckland, New Zealand	marketed	Local anesthetic; Class IB antiarrhythmic agent	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Class IB antiarrhythmic agent class)

Lupin Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oral Capsule Mexiletine (IR) — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-capsule-mexiletine-ir. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab